| Mgmt Confidence | Highly confident in VK2735 differentiation and competitive 22% weight loss trajectory. |
|---|---|
| Demand Visibility | Targeting 1 billion global obesity patients; currently only 5% receiving therapy. |
| Segment Growth | Sub-Q VK2735 in phase 3; Oral VK2735 in phase 3 Sunrise trials. |
| New Clients | KOLs from Pennington Biomedical, Northwestern, and Weill Cornell joined the presentation. |
| Capex & Debt | VK2809 and VK0214 programs are currently available for licensing. |
| Regulatory | Generic and brand names for VK2735 currently undergoing approval process. |
| Commentary | Focusing on maintenance flexibility with monthly dosing retaining 90% of weight loss. |
| New Launches | VK3019 Amylin agonist entering multiple ascending dose study in Q1 2026. |
Growth
VK2735 showed 14.7% weight loss in 13 weeks; 19% placebo-adjusted loss in 21 weeks.
Outlook
Vanquish phase 3 extension starts Q1 2027; oral Sunrise data expected in 2028.
Risks
Management used aspirational language for 2028 data; no hard financial guidance or revenue numbers provided.
The company's earnings call, NASDAQ: VKTX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Viking Therapeutics, Inc.: key numbers
- Share price
- $26.80Close, Nov 16
- Market cap
- $3.42B
- Shares outstanding
- 127.52MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Viking Therapeutics, Inc.
All →Viking Therapeutics Q3 2026 Results: Net Loss of $183M, Loss Widens
Viking Therapeutics reported a net loss of $469.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $432.7 million. The company strengthened its balance sheet through public offerings and convertible senior notes, ending the period with $677.6 million in cash and cash equivalents.
- Key figure
- Net loss $183M
Viking Therapeutics Financial Results
Viking Therapeutics reported third quarter 2026 financial results and provided a corporate update on its obesity franchise, including the initiation of the SUNRISE Phase 3 program for oral VK2735. The company ended the quarter with a strong cash position of $960 million following upsized public offerings of common stock and convertible notes. Clinical progress continues across its pipeline, including the ongoing VANQUISH Phase 3 trials and the Phase 1 study of amylin agonist VK3019.
“During the third quarter, Viking continued to advance and expand development activities in its obesity franchise. We recently announced the initiation of the SUNRISE Phase 3 program with the oral tablet formulation of VK2735, representing the third and fourth registration trials to be underway. The SUNRISE oral Phase 3 program will closely mirror the ongoing VANQUISH Phase 3 program evaluating the subcutaneous formulation and we are excited to have these important clinical trials underway.”
Brian Lian, Ph.D., President and Chief Executive Officer
“To support our robust pipeline, as well as the activities related to the potential commercial launch of VK2735, during the quarter the company successfully closed concurrent upsized public offerings of common stock and convertible senior notes, resulting in a strong quarter-end cash balance of $960 million. This provides the company with the runway to execute multiple Phase 3 trials and build the infrastructure to execute a strong and effective commercial strategy.”
Brian Lian, Ph.D., President and Chief Executive Officer
Viking Therapeutics Capital Raise of $316M
Viking Therapeutics closed a public equity offering of 9,035,714 shares of common stock at $35.00 per share, including the full exercise of the underwriters' overallotment option. The company raised approximately $297.0 million in net proceeds from the equity portion. Simultaneously, the company issued $258.75 million in 2.00% Convertible Senior Notes due 2032 to further strengthen its balance sheet.
- Value
- $316M
- Counterparty
- Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC
Viking Therapeutics Clinical Trial Data
Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, demonstrating that less frequent dosing (monthly and every other week) effectively maintained weight loss. Subjects receiving weekly 17.5 mg doses achieved 22% placebo-adjusted weight loss at Week 33, and the drug showed excellent tolerability with GI adverse event rates similar to placebo during the maintenance phase.
- Earnings call
- Sep 29, 2026, 8:00 AM ET
“The results of our innovative maintenance dosing study continue to demonstrate the significance of VK2735’s unique and differentiated half-life and PK profile, which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity.”
Brian Lian, Ph.D., chief executive officer of Viking
“We believe this dose-ranging study clearly demonstrated the potential viability of novel, extended dosing approaches for maintenance following induction with an incretin-based therapy.”
Brian Lian, Ph.D., chief executive officer of Viking